Dr Sharman on Relapsed Diffuse Large B Cell Lymphoma (DBLC)

Dr Sharman on Relapsed Diffuse Large B Cell Lymphoma (DBLC)

Dr Sharman's latest blog looks at how R-CHOP became established as the most commonly used standard of care for DBLC (i.e. how patients fared better when rituximab was added to the existing CHOP therapy) and what options are available for relapsed DBLC patients.

While not specifically relevant to CLL, it may be of interest due to the discussion on how available options (including bone marrow stem cell transplants) are explored for relapsed blood cancer patients.

cll-nhl.com/2014/01/relapse...

Neil

oldestnewest

You may also like...